Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OrienX010 and Toripalimab in Melanoma with Liver Metastasis
NCT04206358Phase 1Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2019
- Primary completion
- Feb 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of orienx010 in melanoma, sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Progression-Free Survival at 16 weeks and Objective Response Rate at 20 months. Status: unknown.
02
Drugs
orienx010
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04206358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04206358.